Salt and crystal of cyclic carbonate nucleoside compound as well as preparation method and application of salt and crystal
By generating hydrobromide crystals of cyclic carbonate nucleoside compounds with high stability and good water solubleness, the problems of existing antiviral drugs being unstable and poor water solubility at room temperature are solved, and the infectivity of the new coronavirus and cats is achieved. Effective treatment and application of peritonitis virus.
Patent Information
- Application Number
- CN202411068927.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-09-19
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-29
AI Technical Summary
Existing antiviral drugs are highly variable and lethal to novel coronavirus (SARS-CoV-2) and other coronaviruses such as cat infectious peritonitis virus (FIPV), lack effective chemotherapy, and existing nucleosides The analogue is a viscous gelatinous substance at room temperature, with poor water solubility and poor chemical stability, making it difficult to use as a pharmaceutical preparation.
Develop a salt and crystal of a cyclic carbonate nucleoside compound, and react with acid to form hydrobromide with high stability and good water soluble hydrobromide. A specific preparation method is used to ensure its physical and chemical stability, forming a needle-like shape Crystals, used to treat diseases caused by coronavirus.
The stability and water solubility of cyclic carbonate nucleoside compounds have been improved, forming solid forms suitable for drug preparations, significantly improving the antiviral activity against novel coronaviruses and cat infectious peritonitis viruses, enhancing the therapeutic effect of drugs and Bioavailability.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a salt and crystal of a cyclic carbonate nucleoside compound, and a preparation method and application thereof. Background Art
[0002] The new coronavirus (SARS-CoV-2) is not only highly transmissible and variable, but also difficult to prevent through vaccines due to its high proliferation capacity. There is currently no effective chemical drug to treat respiratory syncytial virus (RSV), which is the primary cause of hospitalization for viral respiratory infections in infants and young children, and seriously endangers children's health. In this context, antiviral drugs, especially nucleoside analogs targeting viral genetic material (DNA or RNA), have become a key response strategy.
[0003] Some coronaviruses can infect a variety of mammals, including cats, pigs, dogs, cattle, horses, and camels. For example, an estimated 40-80% of cats worldwide carry feline coronavirus (FCoV), which is divided into two subtypes. In particular, the feline infectious peritonitis virus (FIPV) type, which is a variant of the feline coronavirus, has an extremely high mortality rate. Similarly, porcine epidemic diarrhea virus (PEDV) also belongs to the coronavirus family, and the morbidity and mortality caused by sows are also quite high. In addition, feline calicivirus (FCV) is a highly variable, single-stranded RNA virus that mainly causes acute upper respiratory tract infections in cats with a high morbidity rate. It is currently believed to be the main cause of feline stomatitis.
[0004] Therefore, there is an urgent need to develop nucleoside analogs with stable physical properties and excellent pharmacokinetic properties to treat various infectious diseases caused by these viruses. Summary of the invention
[0005] In view of the shortcomings of the prior art, the present invention provides a salt of a cyclic carbonate nucleoside compound, a crystal, a preparation method and an application thereof. The salt of a cyclic carbonate nucleoside compound and its crystal provided by the present invention have the characteristics of simple preparation, high reproducibility, good physical and chemical stability and the like.
[0006] In a first aspect, the present invention provides a salt of a cyclic carbonate nucleoside compound having a structure as shown in Formula I,
[0007] Wherein: Y is hydrochloric acid, sulfuric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, maleic acid, succinic acid, tartaric acid, hydroiodic acid, fumaric acid, benzoic acid, phthalic acid, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, camphoric acid, camphorsulfonic acid, salicylic acid, trifluoroacetic acid, acetic acid, perchloric acid, malic acid, formic acid, propionic acid, malonic acid, oxalate, naphthalenesulfonic acid, acetylsalicylic acid, aspartic acid, glutamic acid, lactic acid, gluconic acid, ascorbic acid, gallic acid, mandelic acid, sorbic acid, taurine, homotaurine, cinnamic acid, mucic acid or a combination thereof, preferably hydrobromic acid or hydrochloric acid; n is 0.5 to 2, preferably 1.
[0008] Preferably, when the positively charged hydrogen ion in Y forms a salt with the nitrogen atom at position 3 in the free base heterocyclic 4-aminopyrrolo[2,1-f][1,2,4]triazine structure of the formula I compound, the formula I compound is a formula I-1 compound, wherein YH represents Y minus one H atom.
[0009]
[0010] Wherein: n is 0.5~2, preferably 1.
[0011] Specifically, when n in the compound of formula I-1 is 1 and Y is hydrobromic acid, the compound is a compound represented by formula I-1'.
[0012]
[0013] In a second aspect, the present invention provides a crystal of a compound represented by formula I-1'. The crystal has a crystal form A or a crystal form B.
[0014] The X-ray powder diffraction pattern of the crystalline form A has characteristic peaks at at least 3 of the following 2θ values, preferably at least 5, and more preferably at least 7: 5.42±0.2°, 10.87±0.2°, 16.56±0.2°, 18.88±0.2°, 21.83±0.2°, 23.81±0.2°, and 27.39±0.2°. In some embodiments, the X-ray powder diffraction pattern of the crystalline form A also has characteristic peaks at at least 3 of the following 2θ values, preferably at least 5, and more preferably at least 8: 25.09±0.2°, 27.02±0.2°, 28.26±0.2°, 29.05±0.2°, 29.84±0.2°, 31.71±0.2°, 33.52±0.2°, and 37.17±0.2°. In some embodiments, the X-ray powder diffraction pattern of Form A is as follows: Figure 1 shown.
[0015] The DSC spectrum of the crystalline form A has an absorption peak at 217±5°C; in some embodiments, the DSC spectrum of the crystalline form A is as follows Figure 2 shown.
[0016] The thermogravimetric analysis (TGA) spectrum of the crystal form A shows that the weight loss is only 0.04% before 105°C, and it slowly loses weight until about 180°C, and then it loses weight rapidly due to sample decomposition, indicating that there is no free water and crystallization solvent in the sample. Figure 3 shown.
[0017] The polarized light microscope image of the crystal form A is as follows Figure 4 As shown, the sample is a needle-shaped crystal with a particle size range of: D10=5μm; D50=13μm; D90=27μm.
[0018] The crystal form A of the compound represented by formula I-1' of the present invention has low hygroscopicity. After being placed under conditions of 25°C and RH 80% for 24 hours, the water content increases to less than 1%, preferably less than 0.2%, and more preferably less than 0.1%.
[0019] The X-ray powder diffraction pattern of the crystalline form B has characteristic peaks at at least 3, preferably at least 5, and more preferably at least 8 of the following 2θ values: 5.33±0.2°, 11.07±0.2°, 19.49±0.2°, 20.19±0.2°, 21.04±0.2°, 25.50±0.2°, 30.31±0.2° and 31.47±0.2°. In some embodiments, the X-ray powder diffraction pattern of the crystalline form B also has characteristic peaks at at least 3, preferably at least 5, and more preferably at least 8 of the following 2θ values: 14.44±0.2°, 16.41±0.2°, 17.20±0.2°, 19.72±0.2°, 21.46±0.2°, 22.88±0.2°, 23.58±0.2°, and 24.26±0.2°. In some embodiments, the X-ray powder diffraction pattern of the crystalline form B is substantially as follows Figure 5 shown.
[0020] In a third aspect, the present invention provides a method for preparing a compound as shown in Formula I or Formula I-1', comprising the following steps: The compound of formula II is dissolved in solvent A to obtain solution A, and the acid or solution B obtained by dissolving the acid in the solvent is mixed with the solution A and stirred to obtain a mixed solution. The mixed solution is continuously stirred to wait for solid precipitation, filtered, and the filter cake is rinsed with an appropriate amount of solvent A, and the target product is obtained after drying.
[0021]
[0022] The compound formula II is recorded in the Chinese patent application CN202210372580.1. This type of compound has significant anti-SARS-COV-2 virus and feline infectious peritonitis virus activity, and also has good inhibitory effects on a variety of other RNA viruses. However, at room temperature, the compound is often a viscous colloid, insoluble in water, easily degraded, with poor chemical stability and poor drugability, especially in the application of pharmaceutical preparations. It causes certain difficulties in the preparation process. Therefore, it is very important to find a solid form of the compound with good water solubility and stable chemical properties.
[0023] The acid is hydrochloric acid, sulfuric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, maleic acid, succinic acid, tartaric acid, hydroiodic acid, fumaric acid, benzoic acid, phthalic acid, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, camphoric acid, camphorsulfonic acid, salicylic acid, trifluoroacetic acid, acetic acid, perchloric acid, malic acid, formic acid, propionic acid, malonic acid, oxalate, naphthalenesulfonic acid, acetylsalicylic acid, aspartic acid, glutamic acid, lactic acid, gluconic acid, ascorbic acid, gallic acid, mandelic acid, sorbic acid, taurine, homotaurine, cinnamic acid, mucic acid or a combination thereof, preferably hydrobromic acid and hydrochloric acid.
[0024] Preferably, in the preparation method, for every 1 g of the compound represented by formula II, the amount of solvent A is 2-20 mL, preferably 1 g: 10-14 mL; the temperature for preparing the mixed solution and waiting for the solid to precipitate is -15-50°C, preferably -5-15°C; the molar ratio of the compound of formula II to the acid is 1:0.5-2, preferably 1:1; the amount of solvent B used for diluting the acid is 1-4 times the volume of the acid, preferably 2-3 times; the stirring time is 0.5-12 hours, preferably 0.5-4 hours; the amount of solvent A used for eluting the filter cake is 4-20 mL, preferably 8-12 mL. The solvent A and solvent B are independently selected from ethyl acetate, acetonitrile, acetone, water and homogeneous mixtures thereof, and both solvent A and solvent B are preferably ethyl acetate.
[0025] When the salt-forming temperature is between 38°C and 42°C, the X-ray powder diffraction pattern of the prepared hydrobromide is as follows: Figure 6 The 2θ value is the same as that of the crystalline form A. Figure 1 Basically the same.
[0026] The X-ray powder diffraction pattern of the crystal form A, a sample baked at 80°C for 24 hours is as follows Figure 7 The 2θ value is the same as that of the crystalline form A. Figure 1 Basically the same.
[0027] The single crystal diffraction of the crystal form A is as follows Figure 8 , and ((3a R ,4 R ,6 R ,6aR )-6-(4-aminopyrrolo[2,1- f [1,2,4]triazine-7-yl)-6-cyano-2-oxotetrahydrofuran[3,4- d The chemical structure of [1,3]dioxol-4-yl)methyl isobutyrate hydrobromide is consistent.
[0028] It should be noted that when hydrobromic acid is used as the acid, the above preparation method produces Form A. As for Form B of the hydrobromide salt of Compound II, its preparation method comprises: The compound of formula II is dissolved in solvent A to obtain solution A, hydrobromic acid or solution B obtained by dissolving hydrobromic acid in solvent B is mixed with the solution A and stirred to obtain a mixed solution, the mixed solution is stirred continuously until no solid is precipitated, and the mixed solution is concentrated under reduced pressure to obtain a jelly. Solvent C is added to the jelly, stirred until a large amount of solid is precipitated, filtered, the filter cake is rinsed with an appropriate amount of solvent C, and the target product is obtained after drying.
[0029] Preferably, for every 1 g of the compound represented by formula II, the amount of solvent A is 1-5 mL, preferably 2-3 mL; the amount of solvent B used for diluting the acid is 1-4 times the volume of the acid, preferably 2-3 times; the stirring time is 10-60 minutes, preferably 30 minutes; the amount of solvent C added to the colloid is 4-20 mL, preferably 8-12 mL; the amount of solvent C used for eluting the filter cake is 4-20 mL, preferably 8-12 mL. The solvent A, solvent B and solvent C are each independently selected from ethyl acetate, acetonitrile, acetone, water and homogeneous mixtures thereof, preferably acetonitrile for solvent A and ethyl acetate for solvent C.
[0030] In a fourth aspect, the present invention provides a pharmaceutical composition comprising the salt of the above-mentioned cyclic carbonate nucleoside compound or the hydrobromide salt crystal of the cyclic carbonate nucleoside compound.
[0031] In a fifth aspect, the present invention provides use of the salt of the above-mentioned cyclic carbonate nucleoside compound, the cyclic carbonate nucleoside compound hydrobromide crystal or the pharmaceutical composition in treating diseases caused by infectious viruses.
[0032] Preferably, the infectious virus includes one or more of the novel coronavirus, feline infectious peritonitis virus, respiratory syncytial virus, porcine epidemic diarrhea virus and feline calicivirus.
[0033] In a sixth aspect, the present invention provides the use of the salt of the above-mentioned cyclic carbonate nucleoside compound, the cyclic carbonate nucleoside compound hydrobromide crystal or the pharmaceutical composition in the preparation of a drug for treating a disease caused by an infectious virus.
[0034] Preferably, the infectious virus includes one or more of the novel coronavirus, feline infectious peritonitis virus, respiratory syncytial virus, porcine epidemic diarrhea virus and feline calicivirus.
[0035] The present invention provides a salt, crystal, preparation method and application of a cyclic carbonate nucleoside compound, wherein the salt of the cyclic carbonate nucleoside compound has a structure shown in Formula I. When it is a hydrobromide salt, it includes a crystalline form A or a crystalline form B, wherein the crystalline form A has the advantages of good physical and chemical stability, good solid properties, good water solubility, low hygroscopicity and high oral bioavailability, and can be used to prepare drugs for treating and / or alleviating related diseases caused by viruses (especially novel coronavirus, feline infectious peritonitis virus, respiratory syncytial virus, porcine epidemic diarrhea virus and feline calicivirus, etc.). BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 The X-ray powder diffraction pattern of the hydrobromic acid (crystalline form A) salt of Compound II is shown.
[0037] Figure 2 The DSC spectrum of the hydrobromic acid (form A) salt of compound II is shown.
[0038] Figure 3 The TGA spectrum of the hydrobromic acid (form A) salt of compound II is shown.
[0039] Figure 4 A polarized light microscope image of the hydrobromic acid (form A) salt of compound II is shown.
[0040] Figure 5 The X-ray powder diffraction pattern of the hydrobromic acid (crystalline form B) salt of Compound II is shown.
[0041] Figure 6 The X-ray powder diffraction pattern of the hydrobromide salt of compound II when the salt formation temperature is 38-42°C is shown.
[0042] Figure 7 The X-ray powder diffraction pattern of the hydrobromic acid (form A) salt of compound II baked at 80°C for 24 hours is shown.
[0043] Figure 8 The single crystal diffraction pattern of the hydrobromic acid (Form A) salt of Compound II is shown. DETAILED DESCRIPTION
[0044] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be described clearly and completely below. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0045] Compound II
[0046] Reagents and consumables description
[0047] In the embodiments of the present invention, the solvents such as ethyl acetate involved in the preparation method are all analytically pure, and unless otherwise specified, the reagents used are not specially treated.
[0048] In the embodiment of the present invention, the room temperature refers to 15-25°C.
[0049] General test methods
[0050] 1. X-ray powder diffraction (XRPD) test method
[0051] Instrument: X-ray polycrystal diffractometer; target: Cu-K β (40 kV, 40 mA); distance from sample to detector: 30 cm; scanning step width: 0.02°; scanning range: 3°~60°; scanning step: 0.1 s.
[0052] Generally, the X-ray powder diffraction angle (2θ value) may have an error within the range of ±0.2°, so the numerical values of the diffraction angle in the present invention should be understood as values also included in the range of about 0.2°. Therefore, the present invention not only covers the crystal form that completely matches the characteristic signal peak in the specific X-ray powder diffraction spectrum, but also covers the crystal form that has an error of about ±0.2° with the characteristic signal peak in the specific X-ray powder diffraction spectrum.
[0053] 2.DSC test method: Instrument: Thermo plus EVO2 differential scanning calorimeter; temperature range: 30~300℃; scanning rate: 10℃ / min.
[0054] 3. Hygroscopicity test method: First, place the stoppered glass weighing bottle in an artificial climate box (temperature 25℃±1℃, relative humidity 80%±2%) for 24 hours, and accurately weigh the weight of the stoppered glass weighing bottle (m1). Take an appropriate amount of the test sample and spread it flat in the stoppered glass weighing bottle that has been placed in the artificial climate box (temperature 25℃±1℃, relative humidity 80%±2%) for 24 hours, and accurately weigh the weight of the stoppered glass weighing bottle at this time (m2). Open the weighing bottle and place it in an artificial climate box (temperature 25℃±1℃, relative humidity 80%±2%) with the bottle cap for 24 hours, then take it out and accurately weigh the weight of the stoppered glass weighing bottle at this time (m3). Calculate the weight gain percentage of the sample.
[0055] 4. Stability test method: The test samples were placed in suitable clean containers and placed under high temperature (80°C), accelerated (40°C, 75%RH), and long-term (25°C / 60%RH) conditions for 7 days. Samples were taken on the 7th day and the appearance of the samples was visually inspected according to the stability inspection items. The content (purity) was detected by HPLC.
[0056] 5. Solubility test method: Take about 10 mg of the test sample and place it in a 10 mL volumetric flask. Add deionized water to make up the volume. Shake vigorously for 30 seconds every 5 minutes at room temperature. After 30 minutes, filter with a 0.45 μm microporous filter membrane, transfer 2 mL of the filtrate to a 10 mL volumetric flask, add acetonitrile to make up the volume as the test sample solution, perform HPLC analysis, and calculate the solubility of the test sample in pure water by the external standard method.
[0057] Example 1: Preparation of the hydrochloride salt of compound II
[0058] ((3a R ,4 R ,6 R ,6a R )-6-(4-aminopyrrolo[2,1- f [1,2,4]triazine-7-yl)-6-cyano-2-oxotetrahydrofuran[3,4- d ][1,3]-Dioxol-4-yl)methyl isobutyrate (1.0 g, 2.58 mmol) was dissolved in ethyl acetate (12 mL), and 36% hydrochloric acid (0.26 g, 2.58 mmol) was added dropwise at room temperature. After the addition was completed, stirring was continued at room temperature for 30 minutes. Solid precipitated and the filter cake was filtered and rinsed with 8 mL of ethyl acetate. The filter cake was dried to obtain the title compound as a white solid (708 mg, yield 64.7%, HPLC purity 99.76%).
[0059] 1 H-NMR (400 MHz, DMSO- d 6): δ 9.87 (s, 1H), 9.20 (s, 1H), 8.27 (s, 1H), 7.43 (d, J = 4.7 Hz, 1H), 7.03 (d, J = 4.7 Hz, 1H), 5.94 (d, J = 7.7 Hz, 1H), 5.51(dd, J = 7.7, 3.7 Hz, 1H), 4.87 (q, J = 4.0 Hz, 1H), 4.35 (dd, J = 12.3, 4.0 Hz,1H), 4.26 (dd, J = 12.3, 5.2 Hz, 1H), 2.45 (h, J = 7.0 Hz, 1H), 1.02 (dd, J = 12.6,7.0 Hz, 6H).
[0060] Example 2: Preparation of the hemisulfate salt of compound II
[0061] ((3a R ,4 R ,6 R ,6a R )-6-(4-aminopyrrolo[2,1- f [1,2,4]triazine-7-yl)-6-cyano-2-oxotetrahydrofuran[3,4- d ][1,3]-dioxol-4-yl)isobutyric acid methyl ester (1.0 g, 2.58 mmol) was dissolved in ethyl acetate (12 mL), and sulfuric acid solution was added dropwise at room temperature. 98% concentrated sulfuric acid (0.13 g, 1.29 mmol) was added to 300 μL of water for dilution. After the addition was completed, stirring was continued at room temperature for 4 h. The reaction solution became viscous and was filtered. The filter cake was rinsed with 8 mL of ethyl acetate and dried to obtain the title compound as a white solid (870 mg, yield 77.2%, HPLC purity 99.26%).
[0062] 1 H-NMR (400 MHz, DMSO- d 6): δ 9.11 (s, 1H), 8.73 (s, 1H), 8.18 (s, 1H), 7.21 (d,J = 4.7 Hz, 1H), 7.00 (d, J = 4.7 Hz, 1H), 5.95 (d, J = 7.7 Hz, 1H), 5.50(dd, J = 7.7, 3.7 Hz, 1H), 4.86 (q, J = 3.9 Hz, 1H), 4.35 (dd, J = 12.3, 3.9 Hz,1H), 4.25 (dd, J = 12.3, 5.2 Hz, 1H), 2.44 (h, J = 7.0 Hz, 1H), 1.01 (dd, J = 13.0,7.0 Hz, 6H).
[0063] Example 3: Preparation of Phosphate Salt of Compound II
[0064] ((3a R ,4 R ,6 R ,6a R )-6-(4-aminopyrrolo[2,1- f [1,2,4]triazine-7-yl)-6-cyano-2-oxotetrahydrofuran[3,4- d Methyl [1,3]-dioxol-4-yl)isobutyrate (1.0 g, 2.58 mmol) was dissolved in ethyl acetate (12 mL), and 85% phosphoric acid (0.15 g, 2.58 mmol) was added dropwise at room temperature. After the addition, stirring was continued at room temperature for 30 minutes. The reaction solution became caked and was filtered. The filter cake was rinsed with 8 mL of ethyl acetate and dried to obtain the title compound as a white solid (934 mg, yield 74.5%, HPLC purity 99.42%).
[0065] 1 H-NMR (400 MHz, DMSO- d 6): δ 8.06 (d, 2H), 7.98 (s, 1H), 6.96 (d, J = 4.6Hz, 1H), 6.91 (d, J = 4.6 Hz, 1H), 6.00 (d, J = 7.7 Hz, 1H), 5.49 (dd, J= 7.7, 3.7Hz, 1H), 4.82 (q, J = 4.0 Hz, 1H), 4.34 (dd, J = 12.2, 4.0 Hz, 1H), 4.23 (dd, J =12.2, 5.2 Hz, 1H), 2.44 (p, J = 7.0 Hz, 1H), 1.00 (dd, J = 13.6, 7.0 Hz, 6H).
[0066] Example 4: Preparation of the Nitrate Salt of Compound II
[0067] ((3a R ,4 R ,6 R ,6a R )-6-(4-aminopyrrolo[2,1- f [1,2,4]triazine-7-yl)-6-cyano-2-oxotetrahydrofuran[3,4- d ][1,3]-Dioxol-4-yl)isobutyric acid methyl ester (1.0 g, 2.58 mmol) was dissolved in ethyl acetate (12 mL), and 65% nitric acid (0.25 g, 2.58 mmol) was added dropwise at room temperature. After the addition was completed, stirring was continued at room temperature for 30 minutes. Solid precipitated and filtered. The filter cake was rinsed with 8 mL of ethyl acetate and dried to obtain the title compound as a white solid (878 mg, yield 75.5%, HPLC purity 99.85%).
[0068] 1 H-NMR (400 MHz, DMSO- d 6): δ 9.49 (s, 1H), 8.98 (s, 1H), 8.25 (s, 1H), 7.29 (d, J = 4.7 Hz, 1H), 7.03 (d, J = 4.7 Hz, 1H), 5.93 (d, J = 7.7 Hz, 1H), 5.51(dd, J = 7.7, 3.7 Hz, 1H), 4.88 (q, J = 4.0 Hz, 1H), 4.35 (dd, J = 12.3, 4.0 Hz,1H), 4.26 (dd, J= 12.3, 5.1 Hz, 1H), 2.45 (h, J = 7.0 Hz, 1H), 1.02 (dd, J = 12.7,7.0 Hz, 6H).
[0069] Example 5: Preparation of the maleate salt of Compound II
[0070] ((3a R ,4 R ,6 R ,6a R )-6-(4-aminopyrrolo[2,1- f [1,2,4]triazine-7-yl)-6-cyano-2-oxotetrahydrofuran[3,4- d Methyl [1,3]-dioxol-4-yl)isobutyrate (1.0 g, 2.58 mmol) was dissolved in ethyl acetate (12 mL), and maleic acid (0.30 g, 2.58 mmol) was added dropwise at room temperature. After the addition, stirring was continued at room temperature for 3 h. Solid precipitated and the solid was filtered. The filter cake was rinsed with 8 mL of ethyl acetate and dried to obtain the title compound as a white solid (878 mg, yield 75.5%, HPLC purity 99.60%).
[0071] 1 H-NMR (400 MHz, DMSO- d 6): δ 8.13 (d, 2H), 8.00 (s, 1H), 6.97 (d, J =4.6 Hz, 1H), 6.92 (d, J = 4.6 Hz, 1H), 6.27 (s, 2H), 5.99 (d, J = 7.7 Hz, 1H),5.49 (dd, J = 7.7, 3.7 Hz, 1H), 4.82 (q, J = 4.0 Hz, 1H), 4.34 (dd, J = 12.3, 4.0Hz, 1H), 4.23 (dd, J = 12.3, 5.2 Hz, 1H), 2.43 (h, J = 7.0 Hz, 1H), 1.01 (dd, J =13.5, 7.0 Hz, 6H).
[0072] Example 6: Preparation of Hydrobromic Acid Salt of Compound II
[0073] ((3a R ,4 R ,6 R ,6a R )-6-(4-aminopyrrolo[2,1- f [1,2,4]triazine-7-yl)-6-cyano-2-oxotetrahydrofuran[3,4- d ][1,3]-Dioxol-4-yl)isobutyric acid methyl ester (1.0 g, 2.58 mmol) was dissolved in ethyl acetate (12 mL), and 48% hydrobromic acid (0.43 g, 2.58 mmol) was added dropwise at room temperature. After the addition, the mixture was stirred at room temperature for 30 minutes. Solid precipitated and was filtered. The filter cake was rinsed with 8 mL of ethyl acetate and dried to obtain a white crystalline solid (1115 mg, yield 92.1%, HPLC purity 99.78%).
[0074] 1 H-NMR (400 MHz, DMSO- d 6): δ 11.34 (s, 1H), 10.31 (s, 1H), 9.54 (s, 1H), 8.44 (s, 1H), 7.64 (d, J = 4.8 Hz, 1H), 7.12 (d, J = 4.8 Hz, 1H), 6.00 (d, J =7.7 Hz, 1H), 5.59 (dd, J = 7.7, 3.6 Hz, 1H), 4.92 (q, J = 3.9 Hz, 1H), 4.48 –4.21 (m, 2H), 2.47 (h, J = 7.0 Hz, 1H), 1.03 (dd, J = 12.8, 7.0 Hz, 6H).
[0075] 13 C-NMR (100 MHz, DMSO- d6): δ 176.10, 153.33, 149.84, 139.06, 125.53,115.62, 114.08, 112.86, 109.46, 83.66, 82.63, 80.75, 79.61, 62.64, 33.46,19.17,19.07.
[0076] MS: m / s 388.1255 [M+1] + .
[0077] X-ray powder diffraction (XRPD) results showed that the obtained solid was in crystalline form, corresponding to Form A, such as Figure 1 shown.
[0078] The differential scanning calorimetry (DSC) analysis results of Form A showed that the obtained solid began to have an endothermic peak at 214.4°C and reached a peak at 217.6°C. Figure 2 shown.
[0079] Thermogravimetric analysis (TGA) and polarized light microscopy images of Form A are shown in Figure 2. Figure 3 and Figure 4 shown.
[0080] The single crystal diffraction pattern of Form A shows that the positively charged hydrogen ions in hydrobromic acid form salts with the nitrogen atom at position 3 in the heterocyclic pyrrolo[2,1-f][1,2,4]triazine structure of Compound II, such as Figure 8 shown.
[0081] Example 7: Preparation of Hydrobromic Acid (Form B) Salt of Compound II
[0082] ((3a R ,4 R ,6 R ,6a R )-6-(4-aminopyrrolo[2,1- f [1,2,4]triazine-7-yl)-6-cyano-2-oxotetrahydrofuran[3,4- d ][1,3]-dioxol-4-yl)isobutyric acid methyl ester (1.0 g, 2.58 mmol) was dissolved in acetonitrile (2.5 mL), and 48% hydrobromic acid (0.43 g, 2.58 mmol) was added dropwise at room temperature. After the addition, stirring was continued at room temperature for 30 minutes. The reaction solution was concentrated under reduced pressure to an oily state, and 12 mL of ethyl acetate was added and stirred to precipitate a large amount of solid. The filter cake was filtered and rinsed with 8 mL of ethyl acetate. The filter cake was dried to obtain a white crystalline solid (1028 mg, yield 85.0%, HPLC purity 99.30%).
[0083] X-ray powder diffraction (XRPD) results showed that the obtained solid was in crystalline form, corresponding to Form B, such as Figure 5 shown.
[0084] Example 8: Preparation of the hydrobromide of compound II with a salt-forming temperature of 38-42°C
[0085] ((3a R ,4 R ,6 R ,6a R )-6-(4-aminopyrrolo[2,1- f [1,2,4]triazine-7-yl)-6-cyano-2-oxotetrahydrofuran[3,4- d ][1,3]-Dioxol-4-yl)isobutyric acid methyl ester (0.5 g, 1.29 mmol) was dissolved in ethyl acetate (6 mL), and 48% hydrobromic acid (0.22 g, 1.29 mmol) was added dropwise at 38-42°C. After the addition, stirring was continued at 38-42°C for 30 minutes. Solid precipitated and was filtered. The filter cake was rinsed with 4 mL of ethyl acetate and dried to obtain a white solid compound (337 mg, 55.8%).
[0086] The obtained solid is in crystalline form, and its X-ray powder diffraction (XRPD) results are as follows: Figure 6 As shown, compared with Form A Figure 1 Basically the same.
[0087] Example 9: Comparison of the physicochemical properties and preparation of compound II and its salts
[0088] (1) Comparison of properties and preparation of compound II and its salt
[0089] Compound II and its different salts (prepared by Examples 1-7) were selected to compare the properties and preparation difficulty. The results are shown in Table 1.
[0090] Table 1 Properties and preparation of compound II and its salts
[0091] As can be seen from Table 1 above, except for the acetate, the other acid addition salt forms of compound II all have good properties. In addition, the hydrobromide, hydrochloride and nitrate of compound II are easier to prepare, especially the hydrobromide presents a distinct white needle-shaped crystalline solid.
[0092] (2) Comparison of hygroscopicity and stability of salts of compound II
[0093] Different salts of compound II (prepared by Examples 1-7) were selected to compare hygroscopicity and stability. High temperature conditions were (80°C), accelerated conditions were (40°C / 75%RH), and long-term conditions were (25°C / 60%RH). The stability results are shown in Table 2, and the hygroscopicity and stability evaluation results are shown in Table 3.
[0094] Table 2 Stability data of compound II and its salt
[0095] As can be seen from Table 2 above, the hydrobromide salt (form A and form B) of compound II is very stable under high temperature, long-term and accelerated conditions, and the stability of the hydrochloride salt of compound II is average; while the stability of the hemisulfate salt, phosphate salt, nitrate salt and maleate salt of compound II is relatively poor.
[0096] Table 3 Hygroscopicity and stability of salts of compound II
[0097] As can be seen from Table 3 above, the hydrobromide salt (crystalline form A and crystalline form B) of compound II is not hygroscopic under the conditions of 25°C and RH80%; the hydrochloride salt, hemisulfate salt, phosphate salt, nitrate salt and maleate salt of compound II are more obviously hygroscopic.
[0098] (3) Comparison of solubility of compound II and its salt
[0099] Compound II and its different salts (prepared by Examples 1-7) were selected to compare the solubility. The results are shown in Table 4.
[0100] Table 4 Solubility of the salt of Compound II in deionized water
[0101] As can be seen from the table above, salt formation significantly increases the water solubility of compound II, and the water solubility and chemical stability of the compound have an important influence on the preparation of pharmaceutical preparations and oral bioavailability. Therefore, salting compound II can significantly improve its water solubility, which will be more conducive to the development of pharmaceutical preparations.
[0102] Example 10: Determination of the composition ratio of the hydrobromide salt of Compound II
[0103] The composition ratio of the hydrobromide salt of compound II was determined by ion chromatography. The results are shown in Table 5.
[0104] Table 5 Composition ratio of the hydrobromide salt of compound II
[0105] As can be seen from Table 5 above, compound II and hydrogen bromide form a salt in a molar ratio of 1:1.
[0106] Test Example 1: Toxic effects of Compound II, its hydrobromic acid (crystalline form A) salt, its hydrochloride salt, GS-441524 and Ribavirin on HEp-2 cells.
[0107] HEp-2 cells were seeded at 6,000 cells per well in 96-well microplates with 100 µL per well and cultured overnight in a 37°C, 5% CO2 incubator. On the second day, 50 μL of gradient dilutions of the test compound II, the hydrobromide salt (crystal form A) of compound II, the hydrochloride of compound II and GS-441524 were added to each well at concentrations of 50 μM, 16.667 μM, 5.556 μM, 1.852 μM, 0.617 μM, 0.206 μM, 0.069 μM, and 0.023 μM. The corresponding concentrations of the positive control Ribavirin were 300 μM, 100 μM, 33.333 μM, 11.111 μM, 3.704 μM, 1.235 μM, 0.412 μM, and 0.137 μM (8 concentration points, 3-fold gradient dilution, triplicate wells), and a blank cell control group (normal cells, no compound treatment) was set up. The final concentration of DMSO in the cell culture medium was 0.5%. The cells were cultured in a 37°C, 5% CO2 incubator for 5 days. Cell viability was detected using CCK-8 reagent and the cell survival rate was calculated. The results showed that compound II, its hydrobromide (crystalline form A), its hydrochloride and GS-441524 had no cytotoxicity to HEp-2 cells at 50 μM and had good safety.
[0108] Test Example 2: In vitro anti-respiratory syncytial virus (RSV) A2 strain activity of Compound II, its hydrobromic acid (crystalline form A) salt, its hydrochloride salt, GS-441524 and Ribavirin.
[0109] HEp-2 cells were seeded in 96-well microplates at 6000 cells per well, and 100 μL per well was cultured overnight in a 37°C, 5% CO2 incubator. The next day, 50 μL of serially diluted compounds (8 concentration points were the same as in Experiment 1, 3-fold serial dilutions, triplicate wells) and 50 μL of virus (200 TCID 50 ). Set up cell control (normal cells, no virus infection or compound treatment) and virus control (cells infected with virus, no compound treatment). The final concentration of DMSO in the cell culture medium is 0.5%. The cells are placed in a 37°C, 5% CO2 incubator for 5 days.
[0110] Use ELISA to detect the expression of viral F protein in each well. Discard the supernatant 5 days after infection, and add 75 μL of 80% acetone to each well to fix the cells. After removing the acetone, add 75 μL of rabbit anti-RSV F protein antibody to each well, incubate at 37°C for 1 h, and wash the plate three times with TBST. Add 75 μL of HRP-labeled goat anti-rabbit IgG antibody to each well, incubate at 37°C for 1 h, and wash the plate three times with TBST. Add 100 μL of TMB colorimetric solution to each well, react at room temperature for 20-30 minutes, and then add 100 μL of 1% HCl to each well to terminate the color reaction. After shaking evenly, use an enzyme reader to read the absorbance value (OD 450 The antiviral activity of the compound was calculated using the raw data obtained. The selectivity index (SI) was calculated using the formula “SI=CC 50 / EC 50 The antiviral activity test results are shown in Table 6.
[0111] Table 6 Cytotoxicity and anti-RSV A2 activity test results of all compounds
[0112] As can be seen from Table 6, the compound II, the hydrochloride salt, the hydrobromide (crystalline form A) salt of the compound II and GS-441524 showed no cytotoxicity within the test range and had good safety; the compound II, the hydrochloride salt, the hydrobromide (crystalline form A) salt of the compound II and GS-441524 all had antiviral activity against the virus strain RSV A2, and the inhibitory effect was significantly better than that of the positive control drug Ribavirin, among which the hydrobromide (crystalline form A) salt had the best activity and the highest selectivity index.
[0113] Test Example 3: Toxic effects of Compound II, its hydrobromic acid (crystalline form A), its hydrochloride and GS-441524 on Vero-E6 cells
[0114] Vero-E6 cells with good growth status were digested with trypsin-EDTA and counted; the cell concentration was adjusted to 2×105 / mL with DMEM culture medium containing 10% fetal bovine serum; the above cell suspension was inoculated into 96-well plates for culture, 100 μL per well, and cultured in 5% CO2, 37℃ for 24 h to form a monolayer. After 24 h, the culture medium was discarded, the cells were washed with PBS, and new DMEM culture medium was replaced after drying. Compound II, hydrobromide (form A) salt of compound II, hydrochloride of compound II and GS-441524 were added respectively at final concentrations of 50 μM, 10 μM, 5 μM, 1 μM, and 0.1 μM. A blank cell control group was also set up. After 48 hours of culture, cell viability was detected using CelITiter-Glo® reagent, and the cell survival rate was calculated. The results showed that at final concentrations of 50 μM, 10 μM, 5 μM, 1 μM, and 0.1 μM, all of the above compounds had no cytotoxicity to Vero-E6 cells and had good safety.
[0115] Experimental Example 4: In vitro anti-SARS-CoV-2 viral activity of Compound II, its hydrobromic acid (form A) salt, its hydrochloride salt and GS-441524.
[0116] Cell preparation: 2×10 Vero-E6 cells were counted 5 / ml 100ul cell suspension per well of a 96-well plate was spread and cultured in a 37°C, 5% CO2 incubator overnight. When the cells grew into a monolayer of cells, they were set aside.
[0117] Virus dilution: Add 0.9 mL of DMEM containing 5% fetal bovine serum to the first tube, and add 1.8 mL to the rest; add 0.1 mL of virus storage solution to the first tube, then use a new pipette tip to draw 0.2 mL from the first tube and add it to the second tube; dilute in multiples to the highest dilution.
[0118] Virus inoculation: Wash the cells once with serum-free DMEM; add 100 μL of different virus dilutions to each well, make a column of wells for each dilution, that is, make 8 parallel wells for each virus dilution, start from the highest dilution when adding samples, set up a negative control, add 100 μL of DMEM containing 5% fetal bovine serum to the negative control wells, detect cell survival, culture at 5% CO2, 37°C for 5 days, observe under a microscope after 5 days, count the number of wells with CPE in each column, and calculate the virus TCID using the KARBER method 50 / mL.
[0119] Virus activity detection: VeroE6 cells were cultured at 2×10 4Each well was inoculated in a 96-well culture plate and cultured at 37 °C for 24 hours to form a monolayer. The initial drug concentration of compound II, compound II hydrobromide (form A) salt, compound II hydrochloride and GS-441524 was 6.0 μM (the solution was 0.5% DMSO in DMEM culture medium solution). After inactivation, they were diluted at 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, and 1:128, and 3 parallel wells were made for each dilution. Then, the drugs to be tested in each dilution of the above groups were mixed with 100 TCID 50 The virus solution was mixed in equal amounts, incubated at 37°C for 1 h, and then inoculated into Vero E6 cells. The cells were cultured at 37°C and 5% CO2 for 5 days, and the highest virus dilution at which 50% of the cells became lesion was observed. A control group was set up at the same time: a cell control (culture medium containing only cells but no virus serum), a negative control (culture medium containing 100 TCID 50 virus, cells and blank serum) and blank control group (culture medium containing 100 TCID 50 Viruses and cells, without serum). According to the degree of cytopathic effect, the Reed-Muench method was used to calculate the 50% drug concentration as the end point, that is, the drug dilution at which 50% of the cells did not produce cytopathic effect (CPE). The test results are shown in Table 7.
[0120] Table 7 Dilution of drug concentration that produces cytopathic effect (CPE) in 50% of cells
[0121] The microplate test was used to evaluate the inhibitory effect of the drug on the new coronavirus (the larger the dilution factor, the higher the activity of inhibiting the virus). It can be seen from Table 7 that the compound II, the hydrobromic acid (crystalline form A) salt of compound II, the hydrochloride of compound II and GS-441524 have significant inhibitory effects on the three mutants of the new coronavirus (BA.5, BF.7 and XBB), among which the inhibitory effects of compound II, the hydrobromic acid (crystalline form A) salt of compound II and the hydrochloride of compound II are significantly better than those of GS-441524.
[0122] Test Example 5: Toxic effects of Compound II, its hydrobromic acid (crystalline form A), its hydrochloride and GS-441524 on CRFK cells
[0123] Gradient dilution of drugs: Weigh compound II, the hydrobromic acid (form A) salt of compound II, the hydrochloride salt of compound II and GS-441524, dissolve them in DMSO respectively, then dilute GS-441524 into 25 mM, 12.5 mM, 6.25 mM, 3.125 mM, 1.5625 mM, 0.390 mM, and 0.098 mM solutions with maintenance medium, dilute the above test drugs into 16 mM, 8 mM, 4 mM, 2 mM, 1 mM, 0.25 mM, and 0.0625 mM solutions with maintenance medium, and make the DMSO concentration to 1.0%, filter and sterilize with a 0.22 μm filter, and store at 4°C for use.
[0124] Determination of drug cytotoxicity: CRFK cells were cultured in a 96-well plate with complete culture medium in advance, and cultured in an incubator at 37°C and 5% CO. After the cells grew into a monolayer, the culture medium in the wells was discarded. 0.1 mL of different dilutions of compound II, compound II hydrobromide (form A), compound II hydrochloride, and GS-441524 were added dropwise to the cell culture wells, and each concentration was repeated in 6 parallel wells. Cell control wells and blank control wells were also set up. After 48 hours of culture, 10 μL of CCK8 reagent was added to each well, and after incubation for another 0.5 hours, the absorbance value (OD) at a wavelength of 450 nm was measured using an enzyme reader. 450 ), the cell survival percentage was calculated according to the control group, cell survival percentage (%) = (average OD of the experimental group-average OD of the blank control group) / (average OD of the cell control group-average OD of the blank control group) × 100%.
[0125] The results of drug cytotoxicity test: After statistical analysis, when the concentration of compound II was 0.87 ≤ 1 mM, the concentration of hydrobromic acid (crystal A) salt of compound II was ≤ 1 mM, the concentration of hydrochloride of compound II was ≤ 0.51 mM, and the concentration of GS-441524 was ≤ 0.39 mM, the OD of each drug concentration group was 450 The values were not different from those of the cell control group (P>0.05), and there was no obvious inhibitory effect on the growth of CRFK cells. That is, the maximum safe concentrations of compound II, the hydrobromic acid (crystalline form A) salt of compound II, the hydrochloride of compound II and GS-441524 were 0.87 mM, 1.0 mM, 0.51 mM and 0.39 mM, respectively.
[0126] Test Example 6: In vitro anti-feline infectious peritonitis virus (FIPV) activity of Compound II, its hydrobromic acid (form A) salt, its hydrochloride salt and GS-441524.
[0127] Virus dilution: dilute the virus solution 10-fold. First, dispense blank DMEM medium into 10 test tubes, 0.9 mL per tube. Take 0.1 mL of virus suspension and add it to the first tube. Mix well to make 10 -1 , in 10 -1 Take 0.1 mL of the virus solution and put it into the second tube and shake it well to make 10 -2 , so diluted to 10 -7 .
[0128] Virus inoculation: Pour out the culture medium of the 96-well plate with a monolayer of CRFK cells, inoculate the diluted virus solution into the wells of the 96-well plate, 0.1 mL per well, set 6 replicates for each dilution, and set up a normal cell control. After inoculation, place them together in a 37°C, 5% CO2 incubator for adsorption for 3 hours. After adsorption, pour out the virus solution, add 0.1 mL of maintenance culture medium (containing 2% FBS) to each well of cells, place them in a 37°C, 5% CO2 incubator for culture, observe the lesion results daily, record the number of lesion wells, and calculate TCID according to the Reed-Muench method. 50 / 100 μL.
[0129] Virus activity detection: add 100 TCID 50 0.1 mL of FIPV virus was adsorbed for 3 h, and the virus solution was poured off. Compound II, compound II hydrobromide (crystalline form A) salt, compound II hydrochloride and GS-441524 were diluted to different compound concentrations of 5 μM, 2.5 μM, 1.25 μM, 0.625 μM, 0.5 μM, 0.3125 μM, and 0.25 μM using maintenance medium containing 0.1% DMSO. 100 μL was added to each well, and 5 replicates were set for each concentration. At the same time, virus control (with virus, no drug solution) and cell control (without virus, no drug solution) were set up. Cultured in a 37°C, 5% CO2 incubator, and the cytopathic effect (CPE) was observed under a microscope every day. When the degree of cytopathic effect in the virus control well reaches 100%, CCK-8 reagent was added to detect the OD of each well. 450 The values were used to calculate the inhibition rate of virus reproduction at different concentrations of compounds, and curves were drawn to calculate the half effective concentration. The test results are shown in Table 8.
[0130] Table 8 Inhibition results of all compounds on feline infectious peritonitis virus
[0131] It can be seen from Table 8 that the compound II, the hydrobromic acid (crystal form A) salt of compound II, the hydrochloride of compound II and GS-441524 all have significant inhibitory effects on feline infectious peritonitis virus, among which the hydrobromic acid (crystal form A) salt of compound II has the best inhibitory effect.
[0132] Test Example 7: In vitro anti-feline calicivirus (FCV) activity of Compound II, its hydrobromic acid (form A) salt, its hydrochloride salt and GS-441524.
[0133] Cell preparation: 96-well plates were plated with 100 ul cell suspension of cat kidney cells (CRFK) at a cell count of 1×105 / ml per well and cultured overnight in a 37°C, 5% CO2 incubator. The plates were divided into experimental group (different drug concentrations), normal cell group (without virus and drug), and virus group (without drug), with 3 replicate wells in each group.
[0134] Virus activity detection: add 100 TCID to each well 50 100 uL of feline calicivirus (FCV) was added, and the supernatant was discarded after overnight adsorption. The cells were washed with PBS and prepared with 400 uM of the drug. The cells were sterilized by filtration, and compound II, hydrobromide (form A) salt of compound II, hydrochloride of compound II, and GS-441524 were diluted with maintenance culture medium to different drug concentrations of 100 uM, 50 uM, 25 uM, 12.5 uM, 6.25 uM, 3.125 uM, 1.5625 uM, and 0.78125 uM. 100 ul was added to each well, and the CPE of the virus group was waited to reach 75%~100%, and CPE was observed. Among them, 0%-25% of the lesions were counted as 1, 25%-50% were counted as 2, 50%-75% were counted as 3, and 75%-100% were counted as 4. The results are shown in Table 9.
[0135] Table 9 The percentage of cytopathic effect (CPE) of all compounds at different drug concentrations
[0136] The inhibitory effect of drugs on feline calicivirus was evaluated by cell cytopathic effect (CPE). It can be seen from Table 9 that when the drug concentration was 12.5 μM, all compounds had significant inhibitory effects on feline calicivirus, and the cytopathic effect rate was less than 50%.
[0137] Test Example 8: Pharmacokinetic evaluation in rats
[0138] Pharmacokinetic process: 21 SD male rats (weight 180-220 g), 3 in each group, fasted for 12 h before the experiment, free drinking water, and 2 h after administration. Compound II, Compound II hydrobromide (crystal form A) salt and GS-441524 were dissolved in appropriate solvents. The solvent for administration was DMSO / propylene glycol / 0.9% NaCl solution. The dosage was 0.103 μmol / kg, and the drug was administered by gavage. After administration, 0.3-0.5 ml of blood was collected from the eye sockets of each group of rats at 0.25, 0.5, 1, 2, 3, 4, 8, and 12 h, respectively, and placed in a 1.5 ml EP tube (heparin pretreatment), centrifuged at 4 ° C, and the upper layer of drug-containing plasma was separated and frozen in a - 80 ° C refrigerator for testing. The concentration of GS-441524 in plasma was determined by LC-MS-MS method, and the pharmacokinetic parameters were calculated.
[0139] Standard curve: Take about 5 ml of blank blood from rats, centrifuge, and take plasma. Take 6 1.5 ml EP tubes, add 0.1, 0.5, 1, 5, 10, 20, and 50 μl of the reserve solution, respectively, make up to 450 μl of the working solvent, mix well, add 50 μl of blank plasma to each, vortex for 5 min, centrifuge for 5 min, take the supernatant, centrifuge again for 5 min, take the supernatant and put it in a 1.5 ml EP tube to obtain 10, 50, 100, 500, 1000, 2000, and 5000 ng / ml GS-441524 standard curve samples (containing internal standard 6,7-Dimethyl-2,3-Bis(2-pyridyl)quinoxaline, QX 100 ng / ml).
[0140] Sample processing: Take 50 μl of the drug-containing plasma obtained in the pharmacokinetic process and put it into a 1.5 ml EP tube with 450 μl of working solvent, vortex for 5 min, take the supernatant, centrifuge again for 5 min, take the supernatant into a 1.5 ml EP tube to obtain the pharmacokinetic test sample of the test compound.
[0141] LC-MS detection: chromatographic column, Kinetex C18 core-shell universal chromatographic column (Phenomenex, USA), column temperature 30℃, injection volume 10 μL, mobile phase acetonitrile-0.6% ammonium formate, flow rate 1.0 ml / min, isocratic elution; ion source, electrospray ionization source ESI; detection method, multiple reaction monitoring (MRM); scanning mode, positive ion mode; ESI spray voltage, ion source temperature 400℃, nebulizing gas flow rate 150 μL / min, backflush drying gas flow rate 100 μL / min.
[0142] The pharmacokinetic results are shown in Table 10.
[0143] Table 10 Pharmacokinetic parameters of all compounds
[0144] Test Example 9: Toxicity test of single oral administration of hydrobromic acid (crystalline form A) salt of compound II to SD rats
[0145] Methods: A total of 50 SD rats (25 / sex) were randomly divided into 5 groups according to body weight, with 10 rats in each group (5 / sex / group). The rats were given a single intragastric administration of solvent (0.5% sodium carboxymethyl cellulose aqueous solution) and hydrobromide (crystalline form A) salt of compound II dissolved in the solvent (5000, 3344, 2236, 1495 and 1000 mg / kg for groups 1 to 5, respectively), with a dosing volume of 10 mL / kg. After administration, the rats were observed for 14 consecutive days, and all animals were dissected on D15. During the experiment, the animals were observed clinically, with body weight, food intake, gross dissection and histopathological examination of abnormal organs observed grossly.
[0146] Results: During the experiment, no death / moribund condition was observed in male animals in each dosing group and female animals in the 1000 mg / kg dose group. Female animals in the ≥1000 mg / kg dose group showed abnormal appearance (red urine color); 7 female animals died in the ≥1495 mg / kg dose group. Female animals showed excessive salivation, eye discharge, emaciation, lethargy, hunched back, prone position, decreased spontaneous activity, nasal discharge, fluffy fur and / or toe gait, and decreased food intake. Male animals showed excessive salivation and eye discharge. Except for the dead animals, no abnormal changes related to the test article were observed in the body weight and weight gain of animals in each dosing group.
[0147] In summary, the responses of male and female animals to the test article differed significantly. The median lethal dose (LD50) of the test article in female rats after acute oral administration was 50 ) is about 3481 mg / kg, LD 50 The 95% confidence limit is 2539-4772 mg / kg, which is low toxicity; no death was observed in male rats, which is practically non-toxic.
[0148] Test Example 10: Dose exploration test of repeated oral administration of the hydrobromic acid salt of Compound II (Crystal Form A) to SD rats for 30 days
[0149] Methods: A total of 64 SD rats (32 / sex) were randomly divided into 7 groups according to body weight. Groups 1 to 4 were used for toxicological studies (5 / sex / group), and groups 5 to 7 (4 / sex / group) were used for toxicokinetic studies. Group 1 was given 0.5% sodium carboxymethyl cellulose aqueous solution as the vehicle control group, and groups 2 and 5, groups 3 and 6, and groups 4 and 7 were given the solvent 0.5% sodium carboxymethyl cellulose aqueous solution and the hydrobromic acid (crystalline form A) salt of compound II dissolved in the solvent (30, 100, and 300 mg / kg, respectively). The animals were gavaged with a volume of 10 mL / kg, once a day, for 30 consecutive days. The animals in groups 1 to 4 were autopsied on the day after the last drug administration (D31). The animals in the toxicokinetic study group were euthanized on the day after the last drug administration (D31) without autopsy.
[0150] During the experiment, the animals were observed clinically, and their weight, food intake, body temperature, ophthalmological examination, clinical pathology, gross anatomy, organ weight and histopathological examination were performed. At the same time, the content of the hydrobromic acid (crystal form A) salt of compound II and its metabolite GS441524 in the samples of the toxicokinetic study animals administered with D1 and D30 were determined, and toxicokinetic analysis was performed.
[0151] Results: During the test, no animals died or were dying. No abnormal changes related to the test article were found in the clinical observation of the 30 mg / kg animals. No abnormal changes related to the test article were found in the ophthalmological examination, urine analysis and gross anatomy of the animals in the 100 mg / kg and 300 mg / kg groups. The main changes included: excessive salivation was observed in the animals in the 100 mg / kg group; excessive salivation, decreased body weight and food intake, and slightly increased hemoglobin (HGB) were observed in the animals in the 300 mg / kg group.
[0152] In summary, under the conditions of this experiment, the hydrobromic acid (crystalline form A) salt of compound II was repeatedly gavaged to SD rats at doses of 30, 100 and 300 mg / kg, once a day, for 30 consecutive days. The maximum tolerated dose (MTD) was 300 mg / kg. At this dose, the average peak concentration (C max ) and the area under the curve AUC last The average peak concentration of GS441524 in female animals was 7398.30 ng / mL and 41061.39 h·ng / mL, respectively. max and the area under the curve AUC last They were 9549.49 ng / mL and 36641.16 h·ng / mL respectively.
[0153] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A salt of a cyclic carbonate nucleoside compound having a structure as shown in Formula I, in, Y is hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, maleic acid, succinic acid, tartaric acid, hydroiodic acid, fumaric acid, benzoic acid, phthalic acid, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, camphoric acid, camphorsulfonic acid, salicylic acid, trifluoroacetic acid, acetic acid, perchloric acid, malic acid, formic acid, propionic acid, malonic acid, oxalic acid, naphthalenesulfonic acid, acetylsalicylic acid, aspartic acid, glutamic acid, lactic acid, gluconic acid, ascorbic acid, gallic acid, mandelic acid, sorbic acid, taurine, homotaurine, cinnamic acid, mucic acid or a combination thereof, preferably hydrobromic acid or hydrochloric acid; n is 0.5~2, preferably 1.
2. A salt of a cyclic carbonate nucleoside compound, characterized in that Its structural formula is shown in Formula I-1: wherein Y is hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, maleic acid, succinic acid, tartaric acid, hydroiodic acid, fumaric acid, benzoic acid, phthalic acid, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, camphoric acid, camphorsulfonic acid, salicylic acid, trifluoroacetic acid, acetic acid, perchloric acid, malic acid, formic acid, propionic acid, malonic acid, oxalic acid, naphthalenesulfonic acid, acetylsalicylic acid, aspartic acid, glutamic acid, lactic acid, gluconic acid, ascorbic acid, gallic acid, mandelic acid, sorbic acid, taurine, homotaurine, cinnamic acid, mucic acid or a combination thereof, preferably hydrobromic acid or hydrochloric acid; n is 0.5~2, preferably 1.
3. A cyclic carbonate nucleoside compound hydrobromide crystal, characterized in that: Its structural formula is shown in Formula I-1': , The crystal has a crystalline form A or a crystalline form B; wherein the crystalline form A has at least one of the following characteristics: 1) Its X-ray powder diffraction pattern has characteristic peaks at at least 3, preferably at least 5, and more preferably at least 7 of the following 2θ values: 5.42±0.2°, 10.87±0.2°, 16.56±0.2°, 18.88±0.2°, 21.83±0.2°, 23.81±0.2°, and 27.39±0.2°; Further preferably, the X-ray powder diffraction pattern of the crystalline form A also has characteristic peaks at at least 3, preferably at least 5, and more preferably at least 8 of the following 2θ values: 25.09±0.2°, 27.02±0.2°, 28.26±0.2°, 29.05±0.2°, 29.84±0.2°, 31.71±0.2°, 33.52±0.2°, and 37.17±0.2°; 2) Its DSC spectrum has an absorption peak at 217±5℃; The X-ray powder diffraction pattern of the crystalline form B has characteristic peaks at at least 3, preferably at least 5, and more preferably at least 8 of the following 2θ values: 5.33±0.2°, 11.07±0.2°, 19.49±0.2°, 20.19±0.2°, 21.04±0.2°, 25.50±0.2°, 30.31±0.2°, and 31.47±0.2°; Further preferably, the X-ray powder diffraction pattern of the crystalline form B also has characteristic peaks at at least 3, preferably at least 5, and more preferably at least 8 of the following 2θ values: 14.44±0.2°, 16.41±0.2°, 17.20±0.2°, 19.72±0.2°, 21.46±0.2°, 22.88±0.2°, 23.58±0.2° and 24.26±0.2°.
4. The cyclic carbonate nucleoside compound hydrobromide crystal according to claim 3, characterized in that: The X-ray powder diffraction pattern of the crystalline form A is substantially as shown in FIG1 ; The X-ray powder diffraction pattern of the crystalline form B is substantially as shown in FIG5 .
5. The method for preparing the cyclic carbonate nucleoside compound hydrobromide crystal according to claim 3 or 4, characterized in that: The crystal has a crystalline form A, and the preparation method comprises the following steps: The compound of formula II is dissolved in solvent A to obtain solution A, hydrobromic acid or solution B obtained by dissolving hydrobromic acid in solvent B is mixed with the solution A and stirred to obtain a mixed solution, the mixed solution is continuously stirred to wait for solid precipitation, filtered, the filter cake is rinsed with an appropriate amount of solvent A, and the target product is obtained after drying; ; Further, The usage ratio of the compound of formula II to the solvent A is 1 g: 2-20 mL, preferably 10-14 mL; The temperature for preparing the mixed solution and waiting for the solid to precipitate is -15 to 50°C, preferably -5 to 15°C; The molar ratio of the compound of formula II to the hydrobromic acid is 1:0.5-2, preferably 1:1; The stirring time is 0.5 to 12 hours, preferably 0.5 to 4 hours; The usage ratio of the compound of formula II to the solvent A for washing the filter cake is 1 g: 4-20 mL, preferably 1 g: 8-12 mL; The solvent A and solvent B are independently selected from ethyl acetate, acetonitrile, acetone, water and homogeneous mixtures thereof, and both solvent A and solvent B are preferably ethyl acetate.
6. The method for preparing the cyclic carbonate nucleoside compound hydrobromide crystal according to claim 3 or 4, characterized in that: The crystal has a crystal form B, and the preparation method comprises the following steps: The compound of formula II is dissolved in solvent A to obtain solution A, hydrobromic acid or solution B obtained by dissolving hydrobromic acid in solvent B is mixed with the solution A and stirred to obtain a mixed solution, the mixed solution is further stirred, no solid is precipitated, and the mixed solution is concentrated under reduced pressure to obtain a jelly; solvent C is added to the jelly, stirred until a large amount of solid is precipitated, filtered, the filter cake is rinsed with an appropriate amount of solvent C, and the target product is obtained after drying.
7. The preparation method according to claim 6, characterized in that: The usage ratio of the compound of formula II to the solvent A is 1 g: 1-5 mL, preferably 1 g: 2-3 mL; The amount of solvent B used for diluting the acid is 1 to 4 times the volume of the acid, preferably 2 to 3 times; The stirring time is 10 to 60 minutes, preferably 30 minutes; The ratio of the compound of formula II to the eluting solvent C is 1 g: 4-20 mL, preferably 1 g: 8-12 mL; The solvent A, solvent B and solvent C are each independently selected from ethyl acetate, acetonitrile, acetone, water and homogeneous mixtures thereof. The solvent A and solvent B are preferably acetonitrile, and the solvent C is preferably ethyl acetate.
8. A pharmaceutical composition comprising a salt of a cyclic carbonate nucleoside compound according to claim 1 or 2 or a cyclic carbonate nucleoside compound hydrobromide crystal according to claim 3 or 4.
9. Use of the salt of the cyclic carbonate nucleoside compound according to claim 1 or 2, or the hydrobromide crystal of the cyclic carbonate nucleoside compound according to claim 3 or 4, or the pharmaceutical composition according to claim 8 in treating diseases caused by infectious viruses; Preferably, the infectious virus includes one or more of the novel coronavirus, feline infectious peritonitis virus, respiratory syncytial virus, porcine epidemic diarrhea virus and feline calicivirus.
10. Use of the salt of the cyclic carbonate nucleoside compound according to claim 1 or 2, or the cyclic carbonate nucleoside compound hydrobromide crystal according to claim 3 or 4, or the pharmaceutical composition according to claim 8 in the preparation of a medicament for treating a disease caused by an infectious virus; Preferably, the infectious virus includes one or more of the novel coronavirus, feline infectious peritonitis virus, respiratory syncytial virus, porcine epidemic diarrhea virus and feline calicivirus.
Citation Information
Cited By
Preparation method for salt of cyclic carbonate nucleoside compound and crystal form thereof
EP4772515A1
